[1]
|
Guastalla, J. and Diéras, V. (2003) The taxanes: Toxicity and quality of life considerations in advanced ovarian cancer. British Journal of Cancer, 89, S16-S22.
doi:10.1038/sj.bjc.6601496
|
[2]
|
Hagiwara, H. and Sunada, Y. (2004) Mechanism of taxane neurotoxicity. Breast Cancer, 11, 82-85.
doi:10.1007/BF02968008
|
[3]
|
Smith, S., Le Beau, M., Huo, D., Karrison, T., Sobecks, R., Anastasi, J., Vardiman, J., Rowley, J. and Larson, R. (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood, 102, 43-52.
doi:10.1182/blood-2002-11-3343
|
[4]
|
Tam, C., Seymour, J., Prince, H., Kenealy, M., Wolf, M., Januszewicz, E. and Westerman, D. (2006) Treatmentrelated myelodysplasia following fludarabine combination chemotherapy. Haematologica, 91, 1546-1450.
|
[5]
|
Whang-Peng, J., Young, R., Lee, E., Longo, D., Schechter, G. and De Vita, V.J. (1988) Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood, 71, 403-414.
|
[6]
|
Armitage, J., Carbone, P., Connors, J., Levine, A., Bennett, J. and Kroll, S. (2003) Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. Journal of Clinical Oncology, 21, 897-906.
doi:10.1200/JCO.2003.07.113
|
[7]
|
Abe, A., Ikawa, H., Muguruma, H. and Maeda, Y. (2008) Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer. (Article in Japanese), Gan To Kagaku Ryoho, 35, 1795-1798.
|
[8]
|
Yeasmin, S., Nakayama, K., Ishibashi, M., Oride, A., Katagiri, A., Purwana, I., Iida, K., Nakayama, N., Ishikura, H. and Miyazaki, K. (2008) Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxeland carboplatin-based chemotherapy in an ovarian cancer patient: A case report and literature review. International Journal of Gynecologic Cancer, 18, 1371-1376.
doi:10.1111/j.1525-1438.2007.01185.x
|
[9]
|
Perry, J., Brown, M. and Gockerman, J. (1998) Acute leukemia following treatment of malignant glioma. Journal of Neurooncology, 40, 39-46.
doi:10.1023/A:1006175831785
|
[10]
|
Noronha, V., Berliner, N., Ballen, K., Lacy, J., Kracher, J., Baehring, J. and Henson, J. (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. Neurological Oncology, 8, 280-283.
doi:10.1215/15228517-2006-003
|
[11]
|
Jager, G., Hofler, G., Linkesch, W. and Neumeister, P. (2004) Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica, 89, ECR1-3.?
|